Propafenone for paroxysmal atrial fibrillation

Stephen C. Hammill, Douglas L. Wood, Bernard J. Gersh, Michael J. Osborn, David R. Holmes

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


Propafenone is a class 1C antiarrhythmic agent potentially effective in paroxysmal atrial fibrillation (AF). Propafenone's effects upon automaticity and conduction in the atrium should decrease the frequency of AF. In the event of a recurrence of AF, its effects on atrioventricular nodal conduction would tend to slow the ventricular response.1-3 Previously, we demonstrated that propafenone was safe and effective for treating patients with refractory complex ventricular ectopic activity4 and paroxysmal supraventricular reentrant tachycardia due to reentry in the atrioventricular node or by an accessory atrioventricular pathway.3 This study reviews our experience with propafenone in patients with paroxysmal AF who had long-term follow-up for control of their rhythm disturbance.

Original languageEnglish (US)
Pages (from-to)473-474
Number of pages2
JournalThe American journal of cardiology
Issue number6
StatePublished - Feb 15 1988

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Propafenone for paroxysmal atrial fibrillation'. Together they form a unique fingerprint.

Cite this